Form 4: Cassava Sciences Director Granted Stock Options Under New Compensation Plan

Cassava Sciences Inc. Director Robert Eugene Anderson Jr. was granted 26,500 stock options as part of the company's amended non-employee director compensation program, approved by stockholders on May 23, 2025.

Summary

• Robert Eugene Anderson Jr., a Director of Cassava Sciences Inc. (SAVA), was granted 26,500 stock options.
• The stock options have an exercise price of $2.11 per share.
• The grant date for these options was May 23, 2025, and they are set to expire on May 23, 2035.
• This grant was made pursuant to the Amended Non-employee Director Compensation Program, which received approval from the company's stockholders on May 23, 2025.
• The granted stock options will vest over a one-year period at a rate of 1/12 per month.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director under a stockholder-approved plan, which is generally positive for aligning interests and governance, without indicating any negative surprises or significant new risks.

Positives

• The grant of stock options to Director Robert Eugene Anderson Jr. aligns his financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The compensation program under which these options were granted was explicitly approved by stockholders, indicating strong shareholder support for the director compensation structure and corporate governance.

Negatives

• The future exercise of these stock options could lead to a slight dilution of existing shares, although this is a common aspect of equity-based compensation.

Risks

• The ultimate value realized from these stock options is contingent on the future market price of Cassava Sciences Inc. common stock appreciating above the exercise price of $2.11, posing a risk if the stock price declines or stagnates.

Future Outlook

The stock options are structured to vest over a one-year period at a rate of 1/12 per month, indicating a future incentive and retention mechanism for the director's continued engagement with the company.

Industry Context

The granting of stock options to non-employee directors is a widely adopted practice across various industries, including biotechnology and pharmaceuticals, serving as a key mechanism to align the interests of board members with the long-term performance and strategic goals of the company.

Comparison to Industry Standards

• The compensation structure involving stock options with a vesting schedule for non-executive directors is a standard and prevalent practice across global industries, including biotechnology, aligning director incentives with shareholder value creation over time.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Eugene Anderson Jr., a director of Cassava Sciences Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Benefit from increased alignment of the director's interests with long-term company performance, though there is a potential for minor future share dilution upon option exercise.
• Director: Receives equity-based compensation, which incentivizes continued dedication and performance, directly linking personal financial outcomes to the company's success.

Next Steps

• The granted stock options will continue to vest monthly over the next year, subject to the director's continued service.

Key Dates

Keywords

SAVA, Cassava Sciences, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Grant, Robert Eugene Anderson Jr.